Table 3 Susceptibilities of Acinetobacter species and the distribution of resistant genes among these species
| Â | No.(%) of isolates: | ||||
|---|---|---|---|---|---|
clinical infection samples | clinical fecal survey samples | Total | |||
A. baumannii (n = 165) | non-baumannii Acinetobacter (n = 5) | A. baumannii (n = 16) | non-baumannii Acinetobacter (n = 58) | Acinetobacter species (n = 244) | |
Antimicrobial agent | |||||
 Amikacin** | 20 (12.1) | 1 (20.00) | 9 (56.3) | 50 (86.2) | 80 (32.8) |
 Gentamycin** | 1 (0.6) | 0 (0) | 5 (31.3) | 13 (22.4) | 19 (7.8) |
 Imipenem | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
 Meropenem | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
 Colistin* | 164 (99.4) | 5 (100) | 16 (100) | 53 (91.4) | 238 (97.5) |
 Ciprofloksacin | 17 (10.3) | 0 (0) | 6 (37.5) | 6 (10.3) | 29 (11.9) |
 Levofloxacin** | 17 (10.3) | 0 (0) | 6 (37.5) | 23 (39.7) | 46 (18.9) |
 Tetracycline** | 1 (0.6) | 0 (0) | 6 (37.5) | 25 (43.1) | 32 (13.1) |
 Trimethoprim-Sulfamethoxazole** | 16 (9.7) | 0 (0) | 5 (31.3) | 18 (31.0) | 39 (16.0) |
Carbapenemase-encoding genes | |||||
class A β-lactamases | |||||
 blaKPC | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
class B metallob-β-lactamases | |||||
 blaIMP | 1 (0.6) | 0 (0) | 0 (0) | 1 (1.7) | 2 (0.8) |
 blaVIM** | 0 (0) | 0 (0) | 2 (12.5) | 2 (3.4) | 5 (2.0) |
 blaSPM | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
 blaNDM** | 0 (0) | 0 (0) | 2 (12.5) | 55 (94.8) | 57 (23.4) |
class D oxacillinases | |||||
 blaOXA-23-like** | 159 (96.4) | 5 (100.0) | 8 (50.0) | 2 (3.4) | 174 (71.3) |
 blaOXA-24-like** | 0 (0) | 0 (0) | 5 (31.3) | 1 (1.7) | 6 (2.5) |
 blaOXA-51-like** | 165 (100) | 4 (80.0) | 13 (81.3) | 0 (0) | 182 (74.6) |
 blaOXA-58-like** | 6 (3.6) | 0 (0) | 0 (0) | 24 (41.4) | 30 (12.3) |
colistin-related resistance gene | |||||
 mcr-1 | 0 (0) | 0 (0) | 0 (0) | 5 (8.6) | 5 (2.0) |
 mcr-2 | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
 mcr-3 | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
 mcr-4 | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
 mcr-5 | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
porins | |||||
 carO** | 144 (87.3) | 3 (60.0) | 15 (93.8) | 2 (3.4) | 164 (67.2) |
drug efflux pumps | |||||
 adeA** | 160 (97.0) | 4 (80.0) | 13 (81.3) | 15 (25.9) | 192 (78.7) |
 adeB** | 160 (97.0) | 4 (80.0) | 15 (93.8) | 18 (31.0) | 197 (80.7) |
 adeC** | 145 (87.9) | 3 (60.0) | 15 (93.8) | 12 (20.7) | 175 (71.7) |
 adeI** | 143 (86.7) | 3 (60.0) | 12 (75.0) | 6 (10.3) | 164 (67.2) |
 adeJ** | 100 (60.6) | 3 (60.0) | 9 (56.3) | 8 (13.8) | 120 (49.2) |
 adeK** | 89 (54.0) | 2 (40.0) | 7 (43.8) | 7 (12.1) | 105 (43.0) |
integron | |||||
 intI1 | 122 (73.9) | 2 (40.0) | 12 (75.0) | 44 (75.9) | 180 (73.8) |
 intI2** | 0 (0) | 0 (0) | 0 (0) | 5 (8.6) | 5 (2.0) |
 intI3 | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
transposon | |||||
 tnpU | 112 (67.9) | 1 (20.0) | 8 (50.0) | 33 (56.9) | 154 (63.1) |
 tnp513* | 119 (72.1) | 4 (80.0) | 9 (56.3) | 34 (58.6) | 166 (68.0) |
insertion sequence | |||||
 IS26 | 159 (96.4) | 5 (100.0) | 16 (100.0) | 58 (100.0) | 238 (97.5) |
 ISAba1 | 150 (90.9) | 5 (100.0) | 14 (87.5) | 55 (94.8) | 224 (91.8) |
 ISAba125 | 154 (93.3) | 5 (100.0) | 14 (87.5) | 57 (98.3) | 230 (94.3) |